Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-Label, Randomized, Multicenter Study of Rocbrutinib (LP-168) vs Pirtobrutinib in Covalent BTK Inhibitor (cBTKi) Pretreated Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Subjects

NCT07342478 is registered in ClinicalTrials.gov with Newave Pharmaceutical Inc as lead sponsor.

NCT NCT07342478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07342478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-Label, Randomized, Multicenter Study of Rocbrutinib (LP-168) vs Pirtobrutinib in Covalent BTK Inhibitor (cBTKi) Pretreated Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Subjects
Lead sponsor
Newave Pharmaceutical Inc
Phase
Phase 3
Overall status
Recruiting
Start date
April 23, 2026
Completion date
July 30, 2030
Enrollment
306 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cll, cll (chronic lymphocytic leukemia), cll / sll, cll progression, cll, refractory, cll, relapsed, sll, sll (small lymphocytic lymphoma)